The ACS Patient Journey: Where Does T2 Diabetes Fit In?

At a Takeda-sponsored symposium held at the 51st Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden, on the 14th September 2015, Prof Jean-Claude Tardif of the Montreal Heart Institute Research Centre, Montreal, Quebec, Canada, describes the epidemiology and clinical management of acute coronary syndrome (ACS) patients and how Type 2 diabetes acts as a risk factor for cardiovascular disease.

The treatment of diabetic post-ACS patients is suboptimal, with an increased risk of short and long-term cardiovascular events and higher rates of long-term mortality compared with non-diabetic patients, and requires an individualised, intensive approach.